newsfilter
← Latest News
PR Newswire·

Elanco Scales Biologics Capabilities with Expansion of Kansas Manufacturing Facility

  • Elanco Animal Health announced the on-time completion of a $120 million, 25,000-square-foot manufacturing expansion at its Elwood, Kansas site on August 26, 2026.
  • The project increases the facility's production capacity by more than four times for monoclonal antibody (mAb) biologics \& includes a new pilot plant, quality control laboratory, \& support spaces.
  • An additional $30 million investment is planned through 2028 for extra warehousing, bringing the total investment to $150 million.
  • The expansion supports the delivery of Elanco's next-generation pipeline, specifically ramping capacity for Befrena™ (tirnovetmab) \& Trutect™, the two mAb products currently manufactured at the site.
  • Customer demand for Befrena™ has exceeded expectations by two times, with unconstrained levels anticipated in early 2027.
  • The facility serves as a critical manufacturing hub for Elanco, one of only two animal health companies with mAb solutions on the market.
  • Burns & McDonnell, a Kansas City-based design-build firm, led the integrated design \& construction services for the project.
  • A survey of 1,409 U.S. pet owners indicates that pet health remains a top budget priority despite rising costs, driving demand for innovative treatments like mAbs.
  • Elanco plans to continue scaling its innovation portfolio by leveraging insights from human health antibody advancements to enhance animal care.